Ac immune receives second milestone and new milestone to increase the potential deal value of lilly morphomer™ tau partnership

Ac immune receives second milestone and new milestone to increase the potential deal value of lilly morphomer™ tau partnership.ac immune sa - will receive a second milestone payment of chf 10 million from eli lilly.ac immune sa - will now also be eligible for a new chf 60 million potential milestone after initiation of tau morphomer phase 2 clinical testing.
ACIU Ratings Summary
ACIU Quant Ranking